PT - JOURNAL ARTICLE AU - Rangwala, Shamina M. AU - Lazar, Mitchell A. TI - The Dawn of the SPPARMs? AID - 10.1126/stke.2002.121.pe9 DP - 2002 Feb 26 TA - Science's STKE PG - pe9--pe9 VI - 2002 IP - 121 4099 - http://stke.sciencemag.org/content/2002/121/pe9.short 4100 - http://stke.sciencemag.org/content/2002/121/pe9.full SO - Sci. STKE2002 Feb 26; 2002 AB - Thiazolidinediones (TZDs) are used as antidiabetic agents in the treatment of type II diabetes. These compounds are ligands for the nuclear hormone receptor PPARγ, which is highly expressed in adipose tissue. PPARγ acts as a molecular switch in the process of fat cell development. The quest for the ideal antidiabetic agent is challenged by the need to develop PPARγ ligands that improve insulin sensitivity, but do not promote fat cell formation. A newly described PPARγ ligand may represent an initial step in this direction and could lead to improved agents for treating insulin resistance in type II diabetes.